Pfizer Readies Q1 Report as Oncology Sales Hit 8% Growth
Oncology accounted for 27% of Pfizer's revenues and grew 8% in 2025, bolstered by Seagen-sourced ADCs such as Padcev and Adcetris while facing generic pressure on Ibrance and Inlyta. Investors await Q1 results on May 5 to gauge sales of Xtandi, Lorbrena, Elrexfio and oncology biosimilars.
1. Oncology Portfolio Overview
Pfizer’s oncology business covers breast, genitourinary, thoracic, gastrointestinal and blood cancers, contributing 27% of total revenues. The segment grew 8% in 2025, bolstered by the 2023 Seagen acquisition which added ADCs such as Padcev, Adcetris, Tukysa and Tivdak.
2. Q1 Sales Drivers and Challenges
Investors expect Q1 results on May 5 to reflect stronger sales of Xtandi, Lorbrena and the Braftovi-Mektovi combination, offsetting declines in Ibrance and Inlyta from generic entry and Medicare Part D redesign. Oncology biosimilars, including six marketed products, are projected to add to revenue growth this quarter.
3. Late-Stage Pipeline and Regulatory Review
Pipeline updates are anticipated for late-stage candidates atirmociclib and sigvotatug vedotin, with regulatory applications under review for sasanlimab in the EU and vepdegestrant in the US. Pfizer plans four pivotal trials in 2026 for PF-08634404, a dual PD-1/VEGF inhibitor licensed from 3SBio.
4. Valuation and Investor Expectations
Pfizer’s stock has gained 24.1% over the past year, lagging the industry’s 27.1% rise, and trades at a 9.24 forward P/E versus a 17.26 industry average and its 10.08 five-year mean. Consensus earnings estimates remain steady at $2.97 for 2026 and $2.82 for 2027, reflecting stable analyst views.